VEGFA and glioblastoma: Since its approval by the US Food and Drug Administration for the treatment of patients with recurrent GBM in 2009, the efficacy of the anti-vascular endothelial growth factor (VEGF)-A humanized monoclonal antibody bevacizumab in combination with SRS has been evaluated in several studies [38, 50, 52].